Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Rani Therapeutics's Ustekinumab Biosimilar?
Ustekinumab Biosimilar is a monoclonal antibody commercialized by Rani Therapeutics, with a leading Phase I program in Psoriatic Arthritis. According...